Canada markets closed
  • S&P/TSX

    -153.99 (-0.76%)
  • S&P 500

    -55.26 (-1.29%)
  • DOW

    -292.30 (-0.86%)

    -0.0030 (-0.38%)

    -0.59 (-0.65%)

    -2,313.12 (-7.77%)
  • CMC Crypto 200

    -36.72 (-6.78%)

    -10.90 (-0.62%)
  • RUSSELL 2000

    -43.38 (-2.17%)
  • 10-Yr Bond

    +0.1090 (+3.78%)

    -260.13 (-2.01%)

    +1.04 (+5.32%)
  • FTSE

    +8.52 (+0.11%)
  • NIKKEI 225

    -11.81 (-0.04%)

    +0.0010 (+0.13%)

CitiusTech Joins HL7’s Vulcan FHIR Accelerator Program to Boost Interoperability in Life Sciences

·2 min read

An initiative to collaborate on the use of data exchange standards such as the HL7 FHIR® standard, for effective data acquisition, exchange and use in translational and clinical research.

PRINCETON, N.J., December 09, 2021--(BUSINESS WIRE)--CitiusTech, a leading provider of healthcare technology solutions, services and platforms, announced today that it is now part of the Health Level Seven International (HL7) Vulcan Accelerator program. Vulcan is the latest HL7 FHIR Accelerator Program to support industry-wide initiatives across clinical care and clinical research. As a Vulcan member, CitiusTech will leverage its HL7 and FHIR capabilities, combined with its interoperability and data management competencies, with the aim of creating an interchangeable and interoperable data ecosystem, for evidence-based insights, patient engagement and decentralized clinical trials.

Bhaskar Sambasivan, CEO of CitiusTech, highlights the value of this collaboration, "We’re excited to join the Vulcan program to enable synergies where FHIR will streamline the sharing of and access to clinical data and support greater and faster therapeutic discoveries. CitiusTech’s involvement in the Vulcan FHIR Accelerator Program will change the way we use data interoperability to improve and enhance healthcare."

Vulcan released the following statement regarding CitiusTech joining the initiative: "Vulcan welcomes CitiusTech as a member of the Accelerator dedicated to the international collaboration of the research community to advance interoperability of data for translational and clinical research. The expertise and enthusiasm that the CitiusTech team will bring to Vulcan is greatly anticipated. We look forward to a successful partnership with CitiusTech."

CitiusTech will support the Vulcan program by developing and recommending new use case proposals, supporting oversight and delivery of projects, and collaborating with industry leaders to offer strategic guidance to the overall program.

More information on the Vulcan FHIR ACCELERATOR Program and the project’s goals can be found here:

About CitiusTech

CitiusTech ( is a leading provider of healthcare technology services, AI/ML & analytics capabilities, platforms and end-to-end packaged solutions to over 120 organizations across the payer, provider, medical technology and life sciences markets. With over 5,400 healthcare technology professionals worldwide, CitiusTech powers healthcare digital transformation through next-generation technologies, solutions and accelerators. Key focus areas include healthcare interoperability data management, quality performance analytics, value-based care, omni channel member experience, connected health, virtual care delivery, real-world data solutions, clinical development, personalized medicine and population health management. CitiusTech has two subsidiaries, FluidEdge Consulting ( and SDLC Partners ( with deep expertise in healthcare consulting and payer technologies, respectively. CitiusTech’s cutting-edge technology expertise, deep healthcare domain expertise and a strong focus on digital transformation enables healthcare organizations to reinvent themselves to deliver better outcomes, accelerate growth, drive efficiencies, and ultimately make a meaningful impact to patients.

View source version on


For CitiusTech - Priyal Shah
Lead, Corporate Communications

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting